These results demonstrated that increased expression of MYC, LARP1, ATG9B, and BCL2L11, as well as decreased expression of DPP4, GSTM2, ATP6V0E1, and STX12 were significantly correlated with poorer RFS and DFS outcomes in NSCLC patients. Here, ATG9B is linked to non-small cell lung carcinoma.